Sign in with Google. Opens in new tab
ENTITY

Oryzon Genomics (ORY SM)

64
Analysis
Health CareSpain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
bullishOryzon Genomics
24 Jun 2025 06:00Issuer-paid

Oryzon Genomics — A step closer to a new treatment paradigm in BPD

Oryzon Genomics has submitted the Phase III clinical trial protocol to the FDA for its lysine-specific demethylase 1 (LSD1) inhibitor, vafidemstat,...

Share
bullishOryzon Genomics
19 May 2025 09:00Issuer-paid

Oryzon Genomics — Preparations in place for an active 2025

Q125 saw Oryzon make significant headway towards Phase III for vafidemstat in BPD and clinical advancement for iadademstat across multiple...

Share
bullishOryzon Genomics
08 May 2025 14:00Issuer-paid

Oryzon Genomics — €13.3m grant improves operating headroom

Oryzon Genomics has been awarded a €13.26m (US$15m) non-dilutive grant under the Med4Cure initiative, part of the Important Project of Common...

Share
bullishOryzon Genomics
24 Apr 2025 17:00Issuer-paid

Oryzon Genomics — Capital raise to support long-term strategy

Oryzon has secured €30m through an equity raise (straight equity, no warrants attached) to support clinical development activities and other...

Share
bullishOryzon Genomics
15 Apr 2025 13:00Issuer-paid

Oryzon Genomics — First patient dosed in iadademstat + ICI SCLC trial

Oryzon Genomics has announced that the first patient has been dosed in iadademstat’s Phase I/II trial, sponsored by the National Cancer Institute,...

Share
x